1160430-66-9Relevant articles and documents
Discovery of novel 2-[(4-hydroxy-6-oxo-2,3-dihydro-1H-pyridine-5-carbonyl)amino]acetic acid derivatives as HIF prolyl hydroxylase inhibitors for treatment of renal anemia
Hamada, Makoto,Takayama, Tetsuo,Shibata, Tsuyoshi,Hiratate, Akira,Takahashi, Masato,Yashiro, Miyoko,Takayama, Noriko,Okumura-Kitajima, Lisa,Koretsune, Hiroko,Kajiyama, Hiromitsu,Naruse, Takumi,Kato, Sota,Takano, Hiroki,Kakinuma, Hiroyuki
, p. 1725 - 1730 (2018)
Prolyl hydroxylase domain-containing protein (PHD) inhibitors are useful as orally administered agents for the treatment of renal anemia. Based on the common structures of known PHD inhibitors, we found novel PHD inhibitor 1 with a 2-[(4-hydroxy-6-oxo-2,3
4-aminofuran-2 (5H) ketone compound and preparation method and application thereof
-
Paragraph 0228-0232, (2020/11/12)
The invention relates to a 4-aminofuran-2 (5H) ketone compound and a preparation method and application thereof. Specifically, the present invention relates to a compound represented by formula (I) ora stereoisomer, a nitrogen oxide or a salt thereof, a m
4-Pyridinylmethyl-Morpholine Derivatives and the use thereof as Medicament
-
Paragraph 0233-0235; 0252-0255, (2020/05/06)
Disclosed are 4-pyridinylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein R1 and R2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing
CRYSTALLINE FORMS OF [(4-HYDROXY-2-OXO-1,2,5,6-TETRAHYDRO-3-PYRIDINYL)CARBONYL]GLYCINE COMPOUND AND METHOD FOR PRODUCING THE SAME
-
Paragraph 0160; 0161, (2017/01/02)
PROBLEM TO BE SOLVED: To provide stable crystalline forms of [(4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine compound in a use environment as a pharmaceutical, and a method for producing the same. SOLUTION: Provided are a type B crystal
2,6-DISUBSTITUTED PYRIDINES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS
-
Page/Page column 61, (2009/07/17)
Disclosed are compounds of formula (I) wherein R1 and R2 are independently selected from hydrogen, halo, CF3, C1-4alkyl and allyl; Y represents (II), (III), (IV) or (V) wherein R3 represents CF3 or C1-4alkyl; and R3a represents CF3 or C1-4alkyl.
